XML 15 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONSOLIDATED BALANCE SHEETS - USD ($)
Apr. 30, 2016
Apr. 30, 2015
CURRENT ASSETS:    
Cash and cash equivalents $ 61,412,000 $ 68,001,000
Trade and other receivables, net 2,859,000 3,813,000
Inventories 16,186,000 7,354,000
Prepaid expenses and other current assets, net 1,351,000 1,355,000
Total current assets 81,808,000 80,523,000
PROPERTY AND EQUIPMENT:    
Leasehold improvements 19,610,000 1,538,000
Laboratory equipment 10,257,000 5,965,000
Furniture, fixtures, office equipment and software 4,045,000 3,991,000
Construction-in-progress 0 11,819,000
Property and equipment, gross 33,912,000 23,313,000
Less accumulated depreciation and amortization (9,610,000) (8,189,000)
Property and equipment, net 24,302,000 15,124,000
Restricted cash 600,000 0
Other assets 2,333,000 1,817,000
TOTAL ASSETS 109,043,000 97,464,000
CURRENT LIABILITIES:    
Accounts payable 8,429,000 10,385,000
Accrued clinical trial and related fees 7,594,000 3,910,000
Accrued payroll and related costs 5,821,000 4,606,000
Deferred revenue 10,030,000 6,630,000
Customer deposits 24,212,000 11,363,000
Other current liabilities 1,488,000 437,000
Total current liabilities 57,574,000 37,331,000
Deferred rent, less current portion 1,395,000 1,098,000
Commitments and contingencies
STOCKHOLDERS' EQUITY:    
Preferred stock - $.001 par value; authorized 5,000,000 shares; issued and outstanding - 1,577,440 and 1,574,764, respectively 2,000 2,000
Common stock - $.001 par value; authorized 500,000,000 shares; issued and outstanding - 236,930,485 and 193,346,627, respectively 237,000 193,000
Additional paid-in-capital 559,111,000 512,464,000
Accumulated deficit (509,276,000) (453,624,000)
Total stockholders' equity 50,074,000 59,035,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 109,043,000 $ 97,464,000